ACKB:EURONEXT BRUSSELSAckermans & van Haaren NV Analysis
Data as of 2026-03-14 - not real-time
€268.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Ackermans & Van Haaren presents a solid value case with a price‑to‑earnings multiple well below the industry average and a modest dividend payout supported by strong cash balances. Fundamental metrics such as a healthy operating margin, positive free cash flow and a low debt‑to‑equity ratio underscore the company’s financial resilience. The dividend yield, while modest, is sustainable given the low payout ratio and ample liquidity. Technical signals suggest a mixed short‑term outlook: the stock trades below its 20‑day moving average and the MACD histogram is negative, indicating bearish momentum, yet it remains above the 50‑day and 200‑day averages, supporting a longer‑term bullish bias. Volume is trending upward, providing a cushion against liquidity concerns. Support around the mid‑260s appears intact, while resistance near the 300 level offers upside potential if the broader market sentiment stays favorable. The overall risk profile is modest, with low beta, controlled volatility and diversified exposure across several stable sectors. Given the current pricing relative to its discounted cash‑flow estimate and peer multiples, the stock is positioned near fair value with a slight upside bias. The dividend’s sustainability and the company’s diversified business model add a defensive layer to the investment case. Investors should weigh the near‑term technical softness against the longer‑term fundamentals and sector positioning.
In the short term, a cautious hold is prudent as the price tests support and MACD remains bearish. For the medium horizon, the combination of undervalued metrics, improving volume and a bullish trend supports a buy recommendation. Over the long run, the company’s diversified operations, stable cash generation and sustainable dividend make it an attractive buy for value‑oriented portfolios.
In the short term, a cautious hold is prudent as the price tests support and MACD remains bearish. For the medium horizon, the combination of undervalued metrics, improving volume and a bullish trend supports a buy recommendation. Over the long run, the company’s diversified operations, stable cash generation and sustainable dividend make it an attractive buy for value‑oriented portfolios.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below 20‑day moving average
- Bearish MACD histogram
- Support level holding firm
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued PE relative to industry
- Increasing volume trend
- Bullish positioning above 50‑day and 200‑day averages
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Diversified business segments
- Sustainable dividend with low payout ratio
- Stable cash flow and modest leverage
Key Metrics & Analysis
Financial Health
Revenue Growth-7.30%
Profit Margin9.94%
P/E Ratio14.8
ROE11.02%
ROA2.24%
Debt/Equity30.48
P/B Ratio1.5
Op. Cash Flow€1.0B
Free Cash Flow€556.9M
Industry P/E29.1
Technical Analysis
TrendBullish
RSI46.0
Support€264.00
Resistance€300.20
MA 20€280.06
MA 50€260.31
MA 200€231.01
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value€230.03
Target Price€291.86
Upside/Downside8.90%
GradeFair
TypeValue
Dividend Yield1.41%
Risk Assessment
Beta0.41
Volatility26.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.